International Journal of Tumor Therapy

International Journal of Tumor Therapy is an international journal publishing original research aticles, critical reviews, research notes, debate and short reports in all areas of tumor therapy. The journal aims to provide a forum for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in tumor therapy related problems.


Ira-Ida Skvortsova

Editor-in-Chief of International Journal of Tumor Therapy

Assistant Professor, Innsbruck Medical University, Austria

Research Areas

Cancer Research, Molecular Biology, Radiation Oncology, Signal Transduction, Carcinoma Stem Cells, Radio-and Chemo-Resistance, Proteomics, Biomarkers

Education

1990-1994PostdocDepartment of Oncology, Altai State Medical University, Barnaul, Russia
1987-1990PostdocDepartment of Clinical Immunology and Allergology, Altai State Medical University, Barnaul, Russia
1981-1987Medicinae Universalis DoctorAltai State Medical University

Experience

2001-presentAss.-Professor in the Department of Therapeutic Radiology and Oncology, University of Innsbruck, Innsbruck, Austria
1998-2000 ESMO Fellowship "Immunological monitoring of clinical trials with cytokines and tumor vaccines", University of Innsbruck, Innsbruck, Austria
1994-1997 Ass.-Professor in the Department of Oncology, Altai State Medical University, Barnaul, Russia

Academic Achievement

1997: Award from the Swiss Anticancer League
2005: Second Prize from Austrian Society for Radiation Oncology (OeGRO) for the research work and publication "Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells." Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T,
2009 First Prize from Austrian Society for Radiation Oncology (OeGRO) for the research work and publication "Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells." Skvortsova I, Skvortsov S, Stasyk S, Raju U, Poppe
2010 First Prize from Austrian Society for Radiation Oncology (OeGRO) for the research work and publication "Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radiore
2011 Kaercher Ring from Austrian Society for Radiation Oncology (OeGRO) for the outstanding achievements in Radiation Oncology

Membership

European Society for Medical Oncology (ESMO)
Austrian Society for Radiation Oncology (OeGRO)
Austrian Cancer Society/Tyrol
EORTC PathoBiology Group (EORTC PBG Contact Person to EORTC Head and Neck Cancer Group and EORTC Radiation Oncology Group)
EORTC Pharmacology and Molecular Mechanisms (PAMM) Group

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, Lukas P, Seppi T. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother. 2004 Aug;16(4):372-80.
[2]  Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K, Zwierzina H. Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol Cancer Ther. 2004 Dec;3(12):1551-8.
[3]  Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, Kamleitner H, Zwierzina H, Lukas P. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.J Radiat Res (Tokyo). 2005 Jun;46(2):241-8.
[4]  Loeffler-Ragg J, Skvortsov S, Sarg B, Skvortsova I, Witsch-Baumgartner M, Mueller D, Lindner H, Zwierzina H. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer. 2005 Oct;41(15):2338-46.
[5]  Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H. Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Apoptosis. 2005 Oct;10(5):1175-86.
[6]  Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, Zwierzina H, Lukas P. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and-independent mechanisms. J Radiat Res (Tokyo). 2006 Jun;47(2):183-96.
[7]  von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. (99m)Tc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1209-18.
[8]  Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Lukas P, Pleiman CM, Zwierzina H. Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines. Mol Cancer Ther. 2007 Jun;6(6):1898-908.
[9]  Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71.
[10]  Skvortsov S, Sarg B, Lindner H, Lukas P, Hilbe W, Zwierzina H, Skvortsova I. Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clin Appl. 2008, 2, 908-914.
[11]  Skvortsova I, Skvortsov S, Stasyk S, Raju U, Popper B-A, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics, 2008 Nov;8(21):4521-33.
[12]  Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol. 2009 Febr;90:280–283.
[13]  Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, Skvortsova I, Schmitz KJ, Martin HJ, Krugmann J, Alakus H, Maser E, Menzel J, Hilbe W, Lindner H, Schmid KW, Zwierzina H. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther. 2009 Jul;8(7):1995-2006.
[14]  Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother Oncol. 2010 July; 96: 108–115.
[15]  Haidenberger A., Fromm-Haidenberger S., de Vries A., Popper B.A., Steurer M., Skvortsova I., Kantner J., Gunsilius E., Lukas P. Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab(®)) for Patients with Non-Hodkin's Lymphoma : Results of a Prospective Phase I/II Study. Strahlenther Onkol. 2011 May;187(5):300-305. Epub 2011 Apr 26.
[16]  Skvortsov S., Jimenez C.R., Knol J.C., Eichberger P., Schiestl B., Debbage P., Skvortsova I., Lukas P. Radioresistant head and neck squamous cell carcinoma cells: intracellular signalling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol. 2011 (in press).
[17]  Skvortsova I, Pustoshilova N. Rectal Carcinoma Yields to Immuno/Chemo Technique. Oncology News, November-December, 21 (6): 3-5; 1995.
[18]  Skvortsova I, Popper B-A, Seppi T, Lukas P. FLT3-ligand administration for the generation of immune response in BALB/c mice during irradiation. Progress in Radio-Oncology VII, Proceedings, 2001: 647-651.
[19]  Schottdorf EM, Skvortsov S, Huber LA, Stasyk T, Lukas P, Skvortsova I. Therapieantwort auf kombinierte Radioimmuntherapie mit Cetuximab. OeGRO-Jahrestagung: Kopf-Hals-Tumoren, Hämatologie & Onkologie 1/2011.